"Proton Pump Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.
Descriptor ID |
D054328
|
MeSH Number(s) |
D27.505.519.389.848
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Proton Pump Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proton Pump Inhibitors".
This graph shows the total number of publications written about "Proton Pump Inhibitors" by people in this website by year, and whether "Proton Pump Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 1 | 2 |
1997 | 1 | 0 | 1 |
1998 | 0 | 2 | 2 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 2 | 1 | 3 |
2004 | 2 | 3 | 5 |
2005 | 3 | 0 | 3 |
2006 | 2 | 2 | 4 |
2007 | 4 | 1 | 5 |
2008 | 4 | 1 | 5 |
2009 | 4 | 6 | 10 |
2010 | 4 | 2 | 6 |
2011 | 5 | 3 | 8 |
2012 | 5 | 6 | 11 |
2013 | 3 | 6 | 9 |
2014 | 4 | 3 | 7 |
2015 | 15 | 5 | 20 |
2016 | 8 | 7 | 15 |
2017 | 6 | 6 | 12 |
2018 | 8 | 5 | 13 |
2019 | 9 | 3 | 12 |
2020 | 7 | 2 | 9 |
2021 | 4 | 3 | 7 |
2022 | 0 | 7 | 7 |
2023 | 1 | 7 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proton Pump Inhibitors" by people in Profiles.
-
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
-
Controversies regarding management of Helicobacter pylori infections. Curr Opin Gastroenterol. 2023 11 01; 39(6):482-489.
-
Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies. Dig Dis Sci. 2023 09; 68(9):3732-3744.
-
PPIs and gastric cancer: any causal relationship? Acta Biomed. 2023 06 14; 94(3):e2023096.
-
Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
-
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
-
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
-
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022; 13:1049908.
-
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGF?-induced lung fibrosis. Sci Rep. 2022 11 30; 12(1):20668.
-
Quality of Studies for Gastric pH Measurements With Vonoprazan. Am J Gastroenterol. 2022 11 01; 117(11):1882.